Trial Profile
Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Edaravone (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms Study 19
- Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation
- 01 Oct 2023 Results of post hoc analysis accessing The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis published in the Muscle and Nerve.
- 17 Aug 2023 According to a Mitsubishi Tanabe Pharma Corporation media release, post-hoc analysis was funded and conducted by MTPA.
- 17 Aug 2023 Results of post-hoc analysis of this trial were published in the Muscle & Nerve.